Conformation-driven design, synthesis and biological evaluation of novel PAK1 inhibitors that downregulate PD-L1 for triple-negative breast cancer therapy.
- DOI
- 10.1016/j.ejmech.2026.119308
- Published
- 2026 Sep 9
- Container
- European journal of medicinal chemistry
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejmech.2026.119308,
title = {Conformation-driven design, synthesis and biological evaluation of novel PAK1 inhibitors that downregulate PD-L1 for triple-negative breast cancer therapy.},
author = {Bao H and Lai Y and Zhao X and Chen W and Chen Z and Guo Y and He Z and Yao D},
year = {2026},
journal = {European journal of medicinal chemistry},
doi = {10.1016/j.ejmech.2026.119308},
url = {https://doi.org/10.1016/j.ejmech.2026.119308}
}RIS
TY - JOUR TI - Conformation-driven design, synthesis and biological evaluation of novel PAK1 inhibitors that downregulate PD-L1 for triple-negative breast cancer therapy. AU - Bao H AU - Lai Y AU - Zhao X AU - Chen W AU - Chen Z AU - Guo Y AU - He Z AU - Yao D PY - 2026 JO - European journal of medicinal chemistry DO - 10.1016/j.ejmech.2026.119308 UR - https://doi.org/10.1016/j.ejmech.2026.119308 ER -
APA
H, B., Y, L., X, Z., W, C., Z, C., Y, G., Z, H., & D, Y. (2026). Conformation-driven design, synthesis and biological evaluation of novel PAK1 inhibitors that downregulate PD-L1 for triple-negative breast cancer therapy.. European journal of medicinal chemistry. https://doi.org/10.1016/j.ejmech.2026.119308
Source records
- pubmed · retrieved 2026-09-25T23:59:52.449Z